Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma

Purpose: Results from the LAUNCH trial suggest transarterial chemoembolization (TACE) in combination with lenvatinib is significantly more effective than lenvatinib as a first-line treatment option for advanced hepatocellular carcinoma (HCC). However, the cost of TACE is substantial. This study comp...

Detaylı Bibliyografya
Asıl Yazarlar:	Ying He, Wangchun Lin, Zhongjie Cai, Yufan Huang, Maojin You, Meisheng Lei, Ruijia Chen
Materyal Türü:	Makale
Dil:	English
Baskı/Yayın Bilgisi:	Frontiers Media S.A. 2023-09-01
Seri Bilgileri:	Frontiers in Pharmacology
Konular:	cost-effectiveness transarterial chemoembolization hepatocellular carcinoma first-line treatment TACE-LEN lenvatinib
Online Erişim:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1219694/full

Benzer Materyaller

Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
Yazar:: Jun-Ning Liu, ve diğerleri
Baskı/Yayın Bilgisi: (2023-02-01)

Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Yazar:: Jun-Ning Liu, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Efficacy and safety of transarterial chemoembolization combined with lenvatinib and camrelizumab in patients with BCLC-defined stage C hepatocellular carcinoma
Yazar:: Juan Wu, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma
Yazar:: Yusuke Kawamura, ve diğerleri
Baskı/Yayın Bilgisi: (2020-10-01)

Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Yazar:: Jiang J, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
Yazar:: Lingzhan Meng, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
Yazar:: Zhao C, ve diğerleri
Baskı/Yayın Bilgisi: (2023-07-01)

Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis
Yazar:: Yue Chen, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

Vascular Normalization Caused by Short-Term Lenvatinib Could Enhance Transarterial Chemoembolization in Hepatocellular Carcinoma
Yazar:: Tetsuya Tachiiri, ve diğerleri
Baskı/Yayın Bilgisi: (2023-05-01)

Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20–40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm
Yazar:: Su Min Cho, ve diğerleri
Baskı/Yayın Bilgisi: (2021-04-01)

Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: a multicenter cohort study
Yazar:: Yushan Zhao, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

Evaluation of different scoring systems for repeating Transarterial Chemoembolization in Egyptian patients with Hepatocellular Carcinoma
Yazar:: Alhaddad Omkolsoum, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Analysis of the efficacy and influence factors for treatment of primary hepatocellular carcinoma by Huachansu tablets combined with transarterial chemoembolization
Yazar:: CHENG Chienshan, ZHANG Tao, WU Junwei, GAO Huifeng, CHEN Jingxian, MENG Zhiqiang
Baskı/Yayın Bilgisi: (2024-07-01)

Transarterial Chemoembolization in Hepatocellular Carcinoma, Albanian Experience.
Yazar:: Ilirian Laçi, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Transarterial chemoembolization with insertion of radioactive seeds for hepatocellular carcinoma
Yazar:: You-Bin Wang, ve diğerleri
Baskı/Yayın Bilgisi: (2023-09-01)

Adjuvant transarterial chemoembolization timing after radical resection is an independent prognostic factor for patients with hepatocellular carcinoma
Yazar:: Hongfa Sun, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

Radiological response in Saudi patients undergoing transarterial chemoembolization for hepatocellular carcinoma
Yazar:: Al Fuhaid Turki, ve diğerleri
Baskı/Yayın Bilgisi: (2007-01-01)

CRAFITY score benefits hepatocellular carcinoma patients treated with transarterial chemoembolization and lenvatinib
Yazar:: Lin Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Efficacy and Safety of Lenvatinib Plus Programmed Death-1 Inhibitors with or Without Transarterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma
Yazar:: Jin M, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01)

Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study
Yazar:: Peng Guo, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization
Yazar:: Tzu-Ping Chien, ve diğerleri
Baskı/Yayın Bilgisi: (2022-09-01)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
Yazar:: Liwei Sun, ve diğerleri
Baskı/Yayın Bilgisi: (2022-09-01)

Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al.
Yazar:: Alessandro Rizzo
Baskı/Yayın Bilgisi: (2021-12-01)

Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor
Yazar:: Qing-Yun Xie, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Conventional transarterial chemoembolization followed by irreversible electroporation for hepatocellular carcinoma
Yazar:: Meng Zhao, ve diğerleri
Baskı/Yayın Bilgisi: (2025-02-01)

Association between transarterial chemoembolization refractoriness and prognosis in Chinese patients with hepatocellular carcinoma: a large retrospective cohort study
Yazar:: Qinxue Sun, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)

Efficacy of radiation plus transarterial chemoembolization and lenvatinib in hepatocellular carcinoma with portal vein tumor thrombus
Yazar:: Aoran Dong, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

Recent technical advances in conventional transarterial chemoembolization for hepatocellular carcinoma in Japan
Yazar:: Hiroki Higashihara, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)

The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer
Yazar:: Yonghua Bi, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

Prediction model of no-response before the first transarterial chemoembolization for hepatocellular carcinoma: TACF score
Yazar:: Jia-Wei Zhong, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects
Yazar:: Masatoshi Kudo
Baskı/Yayın Bilgisi: (2022-10-01)

Role of drug-eluting beads versus conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma
Yazar:: Mahmoud Abu Elfadl, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study
Yazar:: Zongren Ding, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Diagnostic value of serum inflammatory markers in predicting early refractoriness of transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer Stage 0, A, and B hepatocellular carcinoma
Yazar:: Junhui Yang, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
Yazar:: Wei‐Jun Wang, ve diğerleri
Baskı/Yayın Bilgisi: (2023-05-01)

Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Lenvatinib and Anti-PD-1 Antibodies for Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
Yazar:: Wu SJ, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
Yazar:: Zhang W, ve diğerleri
Baskı/Yayın Bilgisi: (2021-07-01)

Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure
Yazar:: Constantine Frangakis, ve diğerleri
Baskı/Yayın Bilgisi: (2021-11-01)

Evaluation of the efficacy of transarterial chemoembolization combined with microwave ablation followed by adjuvant therapy in patients with hepatocellular carcinoma
Yazar:: Bowen Men, ve diğerleri
Baskı/Yayın Bilgisi: (2024-02-01)

Construction of a prognostic model for hepatocellular carcinoma patients receiving transarterial chemoembolization treatment based on the Tumor Burden Score
Yazar:: Jiawei Lin, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)